z-logo
open-access-imgOpen Access
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia
Author(s) -
Lu Cao,
Weilong Zhang,
Xiaoni Liu,
Ping Yang,
Jing Wang,
Kai Hu,
Xiuru Zhang,
Weiyou Liu,
Xue He,
Hongmei Jing,
Xiaoliang Yuan
Publication year - 2019
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/s41598-019-53563-x
Subject(s) - myeloid leukemia , oncology , medicine , leukemia , proportional hazards model , cytogenetics , survival analysis , myeloid , disease , acute leukemia , gene , cancer research , biology , genetics , chromosome
Acute myeloid leukemia (AML) is a malignant hematological disease in which nearly half have normal cytogenetics. We have tried to find some significant molecular markers for this part of the cytogenetic normal AML, which hopes to provide a benefit for the diagnosis, molecular typing and prognosis prediction of AML patients. In the present study, we calculated and compared the gene expression profiles of cytogenetically normal acute myeloid leukemia (CN-AML) patients in database of The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and dataset Vizome (a total of 632 CN-AML samples), and we have demonstrated a correlation between PDE7B gene and CN-AML. Then we proceeded to a survival analysis and prognostic risk analysis between the expression levels of PDE7B gene and CN-AML patients. The result showed that the event-free survival (EFS) and overall survival (OS) were significantly shorter in CN-AML patients with high PDE7B levels in each dataset. And we detected a significantly higher expression level of PDE7B in the leukemia stem cell (LSC) positive group. The Cox proportional hazards regression model showed that PDE7B is an independent risk predictor for CN-AML. All results indicate that PDE7B is an unfavorable prognostic factor for CN-AML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here